Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

about

Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease

P2860

Q57210495-2ABD1397-2ECF-4CDE-B3B7-4210D628F667 Q58765841-C24C1791-06BC-46CD-824C-9DFCA647D780

P2860

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

Item

http://www.wikidata.org/entity/Q47551310

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

@en

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

@nl

type

Item

label

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

@en

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

@nl

prefLabel

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

@en

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

@nl

P1476

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

@en

P2093

Bonnie Leung

http://www.w3.org/2001/XMLSchema#string

Jimmy Chong

http://www.w3.org/2001/XMLSchema#string

Phillippa Poole

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease

Measuring inconsistency in meta-analyses

Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis

Cyclic nucleotide phosphodiesterases

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.

Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

P304

CD002309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1002/14651858.CD002309.PUB5

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28922692

http://www.w3.org/2001/XMLSchema#string

P932

6483682

http://www.w3.org/2001/XMLSchema#string

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

about

P2860

P2860

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932